Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Spero Therapeutics, Inc. on June 23, 2026. The filing details the outcomes of shareholder votes regarding corporate governance, capital structure, and executive compensation.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Stock Incentive Plan Approval: Shareholders approved the 2026 Stock Incentive Plan, authorizing the issuance of up to 12,895,866 shares of common stock.
- Authorized Share Increase: Shareholders approved an amendment to the Certificate of Incorporation, doubling the authorized common stock from 120,000,000 to 240,000,000 shares.
- Board Elections: Milind Deshpande, Ph.D., and Kathleen Tregoning were reelected as Class III directors.
- Accounting Firm Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: The advisory vote on named executive officer compensation was approved.
Voting Results and Management Commentary
Of the 57,901,493 shares eligible to vote, a quorum of 41,061,190 shares (approximately 70.91%) was present. Key voting outcomes included:
- Director Elections: Milind Deshpande received 26,745,670 votes for; Kathleen Tregoning received 28,259,925 votes for.
- Share Authorization: The amendment to increase authorized shares received 30,356,780 votes for, with 10,558,645 votes against.
- Stock Plan: The 2026 Stock Incentive Plan received 25,379,610 votes for, with 3,567,416 votes against.
- Compensation Advisory Vote: Received 27,890,254 votes for, with 1,002,982 votes against.
The filing does not contain specific management commentary, risk factors, or contingencies beyond the standard incorporation of the Proxy Statement and Plan documents by reference.
Investor Verification Checklist
- Verify the dilution impact of the newly authorized 12,895,866 shares under the 2026 Stock Incentive Plan.
- Review the full text of the 2026 Stock Incentive Plan (Exhibit 99.1) for vesting schedules and eligibility criteria.
- Confirm the effective date of the Certificate of Amendment (filed June 23, 2026) regarding the increase to 240,000,000 authorized shares.
- Check the Proxy Statement filed on April 27, 2026, for detailed rationale behind the share increase and compensation metrics.